{"entity":{"id":"nct06462183","kind":"trial","name":"Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)","aka":[],"tldr":"A phase 1 trial of RGT-61159 run by Rgenta Therapeutics Inc, active and no longer recruiting.","summary":"Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) is a phase 1 interventional study registered as NCT06462183 by Rgenta Therapeutics Inc, with 105 participants planned, started 2024-08-19. Conditions recorded: Adenoid Cystic Carcinoma and Colorectal Cancer. Interventions recorded: RGT-61159 and lenvatinib.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06462183","url":"https://clinicaltrials.gov/study/NCT06462183"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["salivary-gland","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["rgt-61159"],"companies":["rgenta-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06462183","phase":"1","setting":"A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)","sponsor":"Rgenta Therapeutics Inc","enrolled":105,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06462183/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"}],"drug":[{"id":"rgt-61159","kind":"drug","name":"RGT-61159","route":"/drugs/rgt-61159/"}],"company":[{"id":"rgenta-therapeutics","kind":"company","name":"Rgenta Therapeutics","route":"/companies/rgenta-therapeutics/"}]}}